Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19

计划入组 60 人 · 首次发布于 2020 年 12 月 9 日

Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome

计划入组 60 人 · 首次发布于 2020 年 4 月 28 日

Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection

计划入组 31 人 · 首次发布于 2020 年 4 月 9 日

Anti-SARS-CoV-2 IgY

Acute Respiratory Distress Syndrome therapy(ImStem Biotechnology, Inc)

immunological directed cellular therapy (oral, acute respiratory distress syndrome)

Edesa Biotech

Canada

Invivyd

United States

Vaxart

United States

European Medicines Agency Recommends Approval of Gohibic for SARS-CoV-2-Induced ARDS

InflaRx's Gohibic (vilobelimab) Receives European Commission Approval for SARS-CoV-2-Induced ARDS

InflaRx's Vilobelimab Receives Positive CHMP Opinion for SARS-CoV-2-Induced ARDS